the use of ngs to better risk stratify patients & identify druggable mutations in mds
Published 1 year ago • 49 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
3:10
the role of ngs in mds diagnosis
-
1:18
key recurrent mutations in mds
-
1:32
next-generation sequencing for low-risk mds
-
3:01
the role of piez01 variants in patients with mds
-
1:01
evolving role of next-generation sequencing in mds
-
2:43
novel therapies in the future of mds treatment
-
1:20
the current standard of care for patients with lower-risk mds
-
4:48
managing and treating mds
-
7:54
patient/caregiver stories - living with mds
-
49:25
myelodysplastic syndrome (mds) and anemia
-
2:04
state-of-the-art treatment for hr-mds
-
1:16
state of the art: mds
-
1:56
the association between mutations and comorbidities in patients with mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
3:38
a new set of treatment options for low-risk mds
-
2:16
current and future treatment approaches for hr-mds
-
3:11
clinical characteristics of h-mds
-
1:04
the future of mds management
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
2:10
using the innate immune system to treat mds & the value of novel immunotherapies
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml